Company news

Stoke Therapeutics, Inc. news in 2024

Stoke Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

December 5, 2024

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

December 3, 2024

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting

December 1, 2024

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

November 4, 2024

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

September 9, 2024

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

September 3, 2024

Stoke Therapeutics to Present at Upcoming Investor Conferences in September

September 2, 2024

Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

September 2, 2024

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

August 6, 2024

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

June 2, 2024

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

May 5, 2024

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer

April 28, 2024

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

April 16, 2024

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 3, 2024

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

March 26, 2024

Stoke Therapeutics Announces Proposed Public Offering

March 25, 2024

Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

March 24, 2024

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome

March 24, 2024

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024

January 7, 2024

Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 3, 2024

Decks in 2024